Danske Bank A S lifted its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 11.9% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 68,602 shares of the medical research company’s stock after acquiring an additional 7,300 shares during the period. Danske Bank A S’s holdings in Natera were worth $28,354,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in NTRA. BlackRock Inc. bought a new stake in shares of Natera in the 2nd quarter valued at about $2,962,770,000. K.J. Harrison & Partners Inc acquired a new stake in Natera in the 2nd quarter valued at about $5,117,000. Abbot Financial Management Inc. acquired a new stake in Natera in the 2nd quarter valued at about $1,537,000. Eagle Health Investments LP bought a new position in Natera during the second quarter worth about $4,302,000. Finally, BlueCrest Capital Management Ltd bought a new position in Natera during the second quarter worth about $11,695,000. 99.90% of the stock is owned by institutional investors.
Natera Stock Down 9.6%
Shares of NTRA stock opened at $288.48 on Tuesday. The company has a 50-day simple moving average of $378.90 and a 200 day simple moving average of $271.87. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.
Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The company had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. The firm’s quarterly revenue was up 34.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.64) EPS. Equities research analysts predict that Natera, Inc. will post -1.25 earnings per share for the current year.
Insider Transactions at Natera
In other news, CFO Michael Brophy sold 470 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $391.49, for a total transaction of $184,000.30. Following the completion of the sale, the chief financial officer owned 45,779 shares in the company, valued at $17,922,020.71. The trade was a 1.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the transaction, the chief executive officer directly owned 87,431 shares in the company, valued at $36,004,085.80. The trade was a 4.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 47,056 shares of company stock worth $17,760,989. Insiders own 5.05% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on NTRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Canaccord Genuity Group raised their price objective on Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, October 19th. JPMorgan Chase & Co. cut their price objective on Natera from $460.00 to $405.00 and set an “overweight” rating for the company in a research report on Friday, November 6th. Robert W. Baird reduced their target price on Natera from $458.00 to $403.00 and set an “outperform” rating for the company in a research note on Monday, November 9th. Finally, Barclays boosted their target price on Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $394.31.
Read Our Latest Research Report on NTRA
About Natera
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
Further Reading
- Five stocks we like better than Natera
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
